Table 1. Cohort of tumor and fat control samples.
Samples with RIN values printed in bold were used for microarray analysis.
| Tumor Samples | Case | Cryo | FFPE | Rearrangement | RIN Cryo | RIN FFPE |
|---|---|---|---|---|---|---|
| MLS 1 | X | X | FUS/DDIT3 | 8.6 | 2.4 | |
| MLS 2 | X | X | FUS/DDIT3 | 2.8 | 2.4 | |
| MLS 3 | X | X | FUS/DDIT3 | 3 | 2.4 | |
| MLS 4 | X | X | FUS | 4.1 | 2.4 | |
| MLS 5 | X | X | FUS | 5.8 | 1.8 | |
| MLS 6 | X | FUS | 2.9 | |||
| MLS 7 | X | EWS1R/DDIT3 | 2.3 | |||
| MLS 8 | X | FUS/DDIT3 | 2.4 | |||
| MLS 9 | X | FUS/DDIT3 | 2.5 | |||
| MLS 10 | X | FUS/DDIT3 | 2.5 | |||
| MLS 11 | X | DDIT3 | 9.3 | |||
| MLS 12 | X | FUS/DDIT3 | 9.4 | |||
| MLS 13 | X | FUS/DDIT3 | 7.9 | |||
| MLS 14 | X | FUS/DDIT3 | 9.4 | |||
| MLS 15 | X | FUS | 9.7 | |||
| MLS 16 | X | FUS/DDIT3 | 7.6 | |||
| Fat Tissue | Case | Cryo | FFPE | Localization | RIN Cryo | RIN FFPE |
| FAT 1 | X | Pericolic | 6.7 | |||
| FAT 2 | X | Pericolic | 5.4 | |||
| FAT 3 | X | Retroperitoneal/perirenal | 7.9 | |||
| FAT 4 | X | Pericolic | 6.4 | |||
| FAT 5 | X | Pericolic | 7.1 | |||
| FAT 6 | X | Pericolic | 7.7 | |||
| FAT 7 | X | Pericolic | 7.4 | |||
| FAT 8 | X | Mamma | 8.0 | |||
| FAT 9 | X | Mamma | 7.4 | |||
| FAT 10 | X | Pericolic | 7.0 | |||
| FAT 11 | X | Mamma | 6.9 | |||
| FAT 12 | X | Pelvine lymph nodes | 7.5 | |||
| FAT 13 | X | Pelvine lymph nodes | 6.4 | |||
| FAT 14 | X | Pericolic | 6.4 | |||
| FAT 15 | X | Mamma | 5.7 |
Cryo: cryo-conserved tissue; FFPE: formalin-fixed, paraffin-embedded tissue; RIN: RNA integrity number; MLS: myxoid liposarcoma.